Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xarelto Label Expansion Plans Slowed By FDA “Complete Response” On ACS Claim

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency’s decision not to approve the Factor Xa inhibitor for treating acute coronary syndrome patients follows a negative recommendation by an FDA advisory committee, which was concerned about missing data in the pivotal ATLAS trial. FDA may be seeking more clarity on the issue of missing vital status follow-up for patients who withdrew consent in that study.

Advertisement

Related Content

FDA Questions Evidence For Janssen’s Xarelto In Acute Coronary Syndrome
FDA Panel To Take Second Look After J&J Plugged Holes In Xarelto ATLAS Data
Xarelto Takes Lead In Exploiting VTE Market Opportunity
ATLAS Trial Design Blamed For Missing Data On Xarelto ACS Use
Xarelto Review Sparks Debate Over Feasibility Of A Three-Drug ACS Regimen
ATLAS Data Not Strong Enough To Support Xarelto’s Use In ACS, FDA Panel Says
Xarelto Filing Puts It Out Ahead In Venous Thromboembolism
Janssen Looks To Differentiate Anticoagulant Xarelto With Broad Label
BMS/Pfizer’s Eliquis On Priority Review Path Toward March 2012 Approval
Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074323

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel